Onesource Pharma Posts Strong Revenue Growth and Returns to Profitability
Onesource Specialty Pharma saw revenue jump 37% YoY and swung to a quarterly profit, marking a sharp recovery from recent losses.
Onesource Specialty Pharma's Q1 FY27 results show a robust 37% revenue growth and a return to profitability, a significant improvement from the loss reported a year ago.
Onesource Specialty Pharma delivered a quarter of strong top-line growth and a decisive return to profitability. Revenue for Q1 FY27 rose sharply by 37.2% year-on-year, while profit swung to ₹25 crore from a near-break-even loss a year ago, signaling a positive operational shift for the contract manufacturer.
The company's performance shows clear sequential improvement. Revenue grew 4.9% from the previous quarter, but the profit jump of 443.5% quarter-on-quarter is more telling. This drove the net profit margin to 5.6%, a substantial recovery from 1.1% in Q4 and a deep loss in Q3. The last five quarters reveal a volatile but improving path.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 449.02YoY +37% | 428.22 | 327.27 |
| Profit (₹ Cr) | 25.0YoY +13258% | 4.6 | -0.19 |
| Net Profit Margin (%) | 5.6YoY +5700% | 1.1 | -0.1 |
Despite the strong quarterly profit, the trailing twelve-month (TTM) figures remain in negative territory, with a net loss of ₹48.62 crore on revenue of ₹1,543.34 crore. This highlights that the company is still working to fully offset the significant loss incurred in Q3 FY26. The stock has faced pressure over the past year, declining 18% to ₹1,553.7, which may reflect past profitability challenges now being addressed.
The key question is whether Onesource can sustain this newfound profitability and continue its revenue momentum into the next quarters to solidify a full-year turnaround.
Live Chart
· ONESOURCE
(BSE)
ISIN: INE013P01021
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.